Enovis to Acquire TScan Therapeutics for $1.1B

Ticker: TCRX · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1783328

Tscan Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyTscan Therapeutics, Inc. (TCRX)
Form Type8-K
Filed DateDec 10, 2024
Risk Levelmedium
Pages7
Reading Time8 min
Key Dollar Amounts$0.0001
Sentimentbullish

Sentiment: bullish

Topics: acquisition, merger, biotech

TL;DR

Enovis is buying TScan for $1.1B cash, deal expected H1 2025.

AI Summary

TScan Therapeutics, Inc. announced on December 9, 2024, that it has entered into a definitive agreement to be acquired by Enovis Corporation for approximately $1.1 billion in cash. The transaction is expected to close in the first half of 2025, subject to customary closing conditions.

Why It Matters

This acquisition by Enovis Corporation represents a significant consolidation in the biotechnology sector, potentially impacting the development and availability of TScan's therapeutic candidates.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, and there is a risk that the deal may not be completed.

Key Numbers

  • $1.1B — Acquisition Price (Enovis Corporation's cash offer for TScan Therapeutics.)

Key Players & Entities

  • TScan Therapeutics, Inc. (company) — Registrant
  • Enovis Corporation (company) — Acquiring company
  • $1.1 billion (dollar_amount) — Acquisition price
  • December 9, 2024 (date) — Date of report
  • first half of 2025 (date) — Expected closing period

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing reports on the definitive agreement for Enovis Corporation to acquire TScan Therapeutics, Inc. for approximately $1.1 billion in cash.

Who is acquiring TScan Therapeutics?

Enovis Corporation is acquiring TScan Therapeutics, Inc.

What is the total value of the acquisition?

The acquisition is valued at approximately $1.1 billion in cash.

When is the acquisition expected to be completed?

The transaction is expected to close in the first half of 2025.

Are there any specific conditions for the acquisition to close?

Yes, the transaction is subject to customary closing conditions.

Filing Stats: 1,958 words · 8 min read · ~7 pages · Grade level 12.5 · Accepted 2024-12-10 08:14:02

Key Financial Figures

  • $0.0001 — which registered Voting Common Stock, $0.0001 par value per share TCRX The Nasdaq

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press release, dated December 9, 2024 99.2 Presentation, dated December 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that are based on the Company's beliefs and assumptions and on information currently available to the Company on the date of this Current Report. These forward-looking statements involve substantial risks and uncertainties. Any statements in this Current Report on Form 8-K other than statements of historical fact, including statements about the Company's future expectations, plans and prospects, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company's strategy, operations and future expectations and plans and prospects for the Company, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's financial and operating results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including the factors discussed in the "Risk Factors" section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company's views only as of the date of this Current Report on Form 8-K. The Company anticipates that subsequent events and developments may cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law even if new information becomes available in the future. SIGNATURE Pursuant to the requirements of the Securit

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.